<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349165</url>
  </required_header>
  <id_info>
    <org_study_id>NL29961</org_study_id>
    <secondary_id>10-374</secondary_id>
    <nct_id>NCT02349165</nct_id>
  </id_info>
  <brief_title>Standard Versus Transepithelial Corneal Crosslinking</brief_title>
  <official_title>Standard Versus Transepithelial Corneal Crosslinking for Treatment of Progressive Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nienke Soeters</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. F.P. Fischer Stichting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Nederlands Oogheelkundig Onderzoek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gold standard corneal crosslinking (CXL) technique involves the initial step of
      epithelial removal, in order to achieve a sufficient treatment effect (meaning: stabilisation
      of progressive keratoconus (KC). Our aim is to evaluate the effects of transepithelial CXL
      (TE-CXL), whereby the epithelium is left intact and the cornea is instead treated by a
      solution composed of 0.1% riboflavin, combined with enhancers, after which standard CXL is
      performed. This solution seems to facilitate riboflavin penetration into the corneal stroma
      through the intact epithelium. The investigators expect to achieve a similar effect of TE-CXL
      with the advantage of a faster healing time and less risk of infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical stabilisation of keratoconus one year after CXL</measure>
    <time_frame>1 year</time_frame>
    <description>Using a Scheimpflug device (Pentacam, Oculus), topography measurements are performed. Clinical stabilisation is defined as an increase of no more than 1 diopter of the maximum keratometry value over the preoperative maximum keratometry value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications, defined as epithelial healing problems and/or keratitis.</measure>
    <time_frame>1 year</time_frame>
    <description>the incidence of epithelial healing problems after treatment will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>epithelium off CXL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ricrolin TE CXL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transepithelial versus epithelium-off CXL</intervention_name>
    <description>A comparison of the CXL procedure with and without epithelium removal</description>
    <arm_group_label>epithelium off CXL</arm_group_label>
    <arm_group_label>Ricrolin TE CXL</arm_group_label>
    <other_name>epithelium-on versus epithelium-ff corneal crosslinking</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ricrolin TE</intervention_name>
    <description>Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation</description>
    <arm_group_label>Ricrolin TE CXL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic riboflavin</intervention_name>
    <description>After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation</description>
    <arm_group_label>epithelium off CXL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented progressive KC (by Pentacam and/or corneal topography imaging).

          -  A clear central cornea.

          -  A minimal corneal thickness of ≥ 400 µm at the thinnest corneal location (Pentacam
             imaging).

          -  Minimal Snellen corrected distance visual acuity of ≥ 0.4.

          -  Patient age of ≥ 18 years.

        For this research study, the inclusion parameters will be the same as mentioned above, with
        the following additional inclusion criteria:

          -  Documented progression of KC, as demonstrated by anterior segment imaging and/or
             corneal topography:

             o Defined an increase in maximal keratometry, steepest keratometry, mean keratometry
             or topographic cylinder value by ≥ 0.5 D over the previous 6 months and/or a decrease
             in thinnest pachymetry

          -  Documented progression of KC defined by increase in refractive cylinder of ≥ 0.5 D
             over the previous 6 months

        Exclusion Criteria:

          -  Presence of corneal scars.

          -  History of epithelial healing problems.

          -  Presence of previous ocular infection (such as herpes keratitis).

          -  Patients who are pregnant and/or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Nienke Soeters</investigator_full_name>
    <investigator_title>BOptom</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

